Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC
Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced…